文献速递妇科

纳武利尤单抗联合新辅助及术后化疗治疗新诊断卵巢癌的初步研究

A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2025-10-31

单中心初步研究纳入21例初治晚期上皮性卵巢癌患者,在标准新辅助化疗(卡铂+剂量密集紫杉醇)基础上加用纳武利尤单抗360 mg每3周一次,行间歇性肿瘤细胞减灭术(ICS)后再化疗3周期。安全性符合已知药物特征,7例(33%)出现归因于纳武利尤单抗的3/4级不良事件;20例可评估患者中15例(75%)达到肉眼完全切除,7例(35%)化疗反应评分(CRS)为3分。中位无进展生存期15.6个月,中位总生存期50.7个月。

要点

  • 纳武利尤单抗联合卡铂和紫杉醇新辅助及术后化疗安全可耐受。
  • 20例可评估患者中15例(75%)在ICS时达到肉眼完全切除。
  • 20例中7例(35%)达到最佳病理化疗反应评分(CRS)3分。

核心结论

  • 纳武利尤单抗联合卡铂和紫杉醇安全且可耐受。
  • 多数患者达到肉眼完全切除,三分之一患者在ICS时达到最佳CRS。
  • 需要进一步研究以识别最可能从初始免疫检查点阻断中获益的卵巢癌患者。

研究设计与样本

  • 单中心初步研究(NCT03245892),纳入21例初治晚期上皮性卵巢癌患者,以新辅助化疗为最合适初始治疗。
  • 治疗方案为静脉纳武利尤单抗360 mg联合标准卡铂和剂量密集紫杉醇新辅助化疗,每3周一次,共3-6周期。
  • 随后行间歇性肿瘤细胞减灭术(ICS),术后再治疗3周期。

主要发现

  • 21例接受治疗患者的安全性结果与已知药物特征一致。
  • 7例(33%)出现归因于纳武利尤单抗的3/4级不良事件,其中1例3级输注反应导致无法评估。
  • 20例可评估患者中15例(75%[95%CI,50.9-91.3%])在ICS时达到肉眼完全切除。
  • 20例中7例(35%[95%CI,15.4-59.2%])达到最佳病理化疗反应评分(CRS)3分。
  • 中位无进展生存期15.6个月(95%CI,11.6-26.4个月),2年率为32.5%(95%CI,12.8-54.1%);中位总生存期50.7个月(95%CI,26.5个月-不可评估),2年率为85%(95%CI,60.4-94.9%)。

临床怎么用

  • 原文结论为纳武利尤单抗联合卡铂和紫杉醇安全且可耐受,多数患者达到肉眼完全切除,三分之一达到最佳CRS。
  • 作者认为需要进一步研究以识别最可能从初始免疫检查点阻断中获益的卵巢癌患者。

局限性

  • 原文为单中心初步研究。
  • 原文结论指出需要进一步研究以识别最可能从初始免疫检查点阻断中获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether the addition of nivolumab to standard neoadjuvant chemotherapy (NACT) in previously untreated advanced-stage epithelial ovarian cancer (EOC) is safe and feasible. METHODS: In this single-institution pilot study (NCT03245892), patients with advanced EOC for whom NACT was considered the most appropriate initial therapy option were treated with intravenous nivolumab 360 mg with standard carboplatin and dose-dense paclitaxel NACT every 3 weeks for 3-6 cycles. Patients then underwent interval cytoreductive surgery (ICS) followed by another 3 cycles of post-operative treatment. RESULTS: Safety results were consistent with the known profile of the study drugs for the 21 patients treated. Seven (33 %) patients had grade 3/4 adverse events attributed to nivolumab, with one case of grade 3 infusion reaction making that patient unevaluable. Fifteen of the 20 (75 % [95 % CI, 50.9-91.3 %]) evaluable patients had complete gross resection at ICS, and 7 of 20 (35 % [95 % CI, 15.4-59.2 %]) achieved an optimal pathologic chemotherapy response score (CRS) of 3. Median progression-free survival was 15.6 months (95 % CI, 11.6-26.4 months), with a 2-year rate of 32.5 % (95 % CI, 12.8-54.1 %). Median overall survival was 50.7 months (95 % CI, 26.5 months-not evaluable), with a 2-year rate of 85 % (95 % CI, 60.4-94.9 %). CONCLUSIONS: The combination of nivolumab with carboplatin and paclitaxel was safe and tolerable. Most patients achieved a complete gross resection and one-third had an optimal CRS at ICS. Further studies are needed to identify patients with ovarian cancer most likely to benefit from upfront immune checkpoint blockade.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Moufarrij S, Friedman CF, Freeman S, et al. A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer. Gynecol Oncol. 2025. PMID: 41175449. doi:10.1016/j.ygyno.2025.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。